Pulmonary pharmacology & therapeutics
-
Pulm Pharmacol Ther · Aug 2012
ReviewCommonalities between the pro-fibrotic mechanisms in COPD and IPF.
COPD and IPF are two chronic lung diseases which are characterized by a decline in lung function, resulting in significant morbidity and mortality. Both of these diseases are more commonly associated with an aging population and the duration for which the disease has been underlying is often unknown. Significant matrix deposition occurs, resulting in either non-reversible airways obstruction in the case of COPD and impaired gas exchange and parenchymal consolidation in IPF. ⋯ Moreover, in the extreme fibrotic setting of IPF, the remodelling is sometimes associated with uncontrolled wound healing responses. As wound healing is a critical aspect to maintaining tissue function and homeostasis, targeting this process directly may result in safety concerns. This review therefore describes some of the recent advances in ascertaining pathways promoting lung fibrosis that may be amenable to therapeutic intervention in both COPD and IPF.
-
Pulm Pharmacol Ther · Aug 2012
ReviewCigarette smoke-induced inflammation and respiratory host defense: Insights from animal models.
While the devastating impact of tobacco on human health is well established, and efforts to reduce its prevalence are ongoing, over 1 billion people continue to smoke. Emerging evidence suggests that cigarette smoking distorts lung immune homeostasis, compromising respiratory host defense. ⋯ In this article, we discuss mechanisms by which cigarette smoke elicits inflammatory processes and how smoking impacts respiratory host defense against viral and bacterial agents. Elucidating cigarette smoke's impacts on lung immune homeostasis will contribute to our understanding of the pathogenesis of chronic obstructive pulmonary disease COPD.